Bio-Rad Laboratories, Inc. BIO

Full chart Compare
Set alert

Price alert · BIO

All alert types
379.99 USD +5.08 (+1.35%)

At closeNov 4, 2026, 4:15 PM EST

379.29 -0.70 -0.18%

After hours · Nov 4, 4:15 PM ET

371.85 Day range 382.00
236.73 52-week range 396.23
YTD
+25.41%
1 year
+22.20%
Market cap
10.16B
Revenue (ttm)
2.59B
Profit margin
8.59%
EPS (ttm)
8.00
Shares out
21.70M
P/E ratio
47.50
Forward P/E
38.97
YTD return
+25.41%
1-year return
+22.20%
Volume
281.80K
Avg volume
253.09K
Open
380.05
Previous close
374.91
Day's range
371.85 – 382.00
52-week range
236.73 – 396.23
Beta
1.06
Analysts
Hold
Price target
335.00 (-11.8%)
Earnings date
Nov 4, 2026

2Y +5.12 (+1.37%)

300400Jan 25Jun 25Nov 25Apr 26Aug 26379.40

Key statistics

Enterprise value
9.78B
PEG ratio
4.01
Price / sales
3.93
Price / book
1.42
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-0.10%
Free cash flow
283.19M
Total cash
1.62B
Total debt
1.37B
Return on equity
3.11%
Short % of float
6.91%
50-day average
374.39
200-day average
313.94

Financials — quick view

All financials
BIO Revenue — quarterly 651.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BIO Net income — quarterly 371.40M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BIO EPS — quarterly 13.89
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

BIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 20262.23———
Aug 4, 2026Jun 30, 20261.752.62+0.87+49.71%
Apr 30, 2026Mar 31, 20261.971.89-0.08-4.06%
Feb 12, 2026Dec 31, 20252.572.51-0.06-2.33%
Oct 29, 2025Sep 30, 20252.302.26-0.04-1.74%
Jul 31, 2025Jun 30, 20251.932.61+0.68+35.23%

Upgrades / downgrades

BIO analyst upgrades and downgrades
DateFirmActionFromTo
Aug 7, 2026RBC CapitalmainOutperformOutperform
Aug 5, 2026CitigroupmainNeutralNeutral
Aug 5, 2026RBC CapitalmainOutperformOutperform
Aug 5, 2026Wells FargomainEqual-WeightEqual-Weight
May 1, 2026Wells FargomainEqual-WeightEqual-Weight
Apr 7, 2026CitigroupdownBuyNeutral

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
bio-rad.com

News

Your note

Sign in to keep a note on BIO — it syncs with the Stock Master app.

Insider holders

BIO insider holders
InsiderRelationLatest transactionDateShares held
ALLISON SCHWARTZDirectorConversion of Exercise of derivative securitySep 3, 20261,734
BARRY JAMESOfficerConversion of Exercise of derivative securitySep 3, 20262,024
COREY COLLEENOfficerConversion of Exercise of derivative securitySep 4, 202519,550
CROWLEY MICHAEL WOfficerSaleMar 13, 20258,171
DIVINCENZO JONATHAN PPresidentConversion of Exercise of derivative securityOct 22, 20262,881
ENGELHARDT EVA ANETTEOfficerConversion of Exercise of derivative securitySep 3, 20261,828

Institution ownership

BIO institution ownership
Holder% heldSharesValueReported
First Eagle Investment Management, LLC12.02%2,606,219989.93MJun 29, 2026
Blackrock Inc.7.84%1,698,929645.31MJun 29, 2026
Dimensional Fund Advisors LP4.36%944,548358.77MJun 29, 2026
Vanguard Capital Management LLC3.81%826,972314.11MJun 29, 2026
Vanguard Portfolio Management LLC3.77%816,198310.02MJun 29, 2026
Ariel Investments, LLC3.77%816,751310.23MJun 29, 2026

Fund ownership

BIO fund ownership
Holder% heldSharesValueReported
First Eagle Funds-First Eagle Global Fund8.67%1,878,739713.61MJul 30, 2026
SmallCap World Fund Inc4.29%930,906353.59MSep 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF2.99%648,604246.36MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.70%584,782222.12MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.95%423,193160.74MJun 29, 2026
Ariel Investment Trust-Ariel Fund1.61%349,270132.66MJun 29, 2026